KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy. PMID 39353164 · J Clin Oncol · 2025-Jan-10 This is a phase III randomized trial in oncology (low-risk cervical cancer) reporting original results. However, it does not meet two mandatory criteria: (1) the intervention is purely surgical (simple vs. radical hysterectomy) with no drug-containing arm, and (2) the primary outcomes reported are sexual health and quality of life (patient-reported outcomes), not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or recurrence-free survival with Kaplan-Meier or hazard ratio analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. PMID 39353163 · J Clin Oncol · 2025-Jan-10 While the record describes an oncology, human, randomized, Phase III trial with a drug intervention and original results, it does not have a primary or key secondary time-to-event efficacy endpoint as required for inclusion in the KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. PMID 39788967 · Nat Commun · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Controlled Trial to Compare AmnioExcel Human Amniotic Allograft in Weekly Versus Biweekly Treatment of Diabetic Foot Ulcers. PMID 39784000 · Int J Low Extrem Wounds · 2025-Jan-09 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. PMID 39476124 · Blood · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study. PMID 39780053 · BMC Anesthesiol · 2025-Jan-08 The trial is randomized and includes cancer patients, but the drug intervention (methylene blue) is for managing septic shock, not for treating the cancer. Therefore, it does not meet the criterion of a drug-containing intervention for oncology. The primary endpoint is also not a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-PD-1 and anti-PD-L1 antibodies for glioma. PMID 39777725 · Cochrane Database Syst Rev · 2025-Jan-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. PMID 39602290 · JAMA · 2025-Jan-07 The study is a randomized trial of a drug (lidocaine) in patients undergoing colon resection, but it is not an oncology trial focused on cancer outcomes. The primary endpoint is a composite measure of gut function recovery (GI-3), not a time-to-event oncology endpoint like OS, PFS, or DFS. While some patients had malignant disease, the trial is not primarily designed or powered for oncology efficacy. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Central ligation or partial preservation of the right gastric artery does not seem to affect conduit or anastomotic perfusion during robot-assisted resection of gastroesophageal junction cancer: a randomized clinical trial. PMID 39558692 · Dis Esophagus · 2025-Jan-07 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
First Measurement: Proactive Immune Cell Sparing in Radiation Therapy. PMID 39830271 · medRxiv · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of different intraoperative blood pressure regulation levels on postoperative myocardial injury in patients undergoing radical mastectomy for breast cancer after receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 39762100 · BMJ Open · 2025-Jan-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 39513948 · Clin Cancer Res · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. PMID 39187984 · Cancer Prev Res (Phila) · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial. PMID 39887069 · Ann Behav Med · 2025-Jan-04 The study is a pilot/feasibility randomized trial for an intervention to improve endocrine therapy adherence, not a Phase III definitive efficacy trial. It does not report time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment. PMID 39739614 · Ann Behav Med · 2025-Jan-04 The study is an online randomized factorial experiment testing behavior change techniques to increase colonoscopy follow-up intentions. While it is human, oncology-related, and randomized, it lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. It is therefore excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 39804646 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials. PMID 39796745 · Cancers (Basel) · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial). PMID 39753246 · BMJ Open · 2025-Jan-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. PMID 39752157 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. PMID 39321347 · Blood · 2025-Jan-02 The record describes a secondary analysis of two randomized trials. The original trials are not explicitly identified as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The analysis itself is a pooled secondary analysis, not the primary report of a definitive Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Role of precise management model in the maintenance of central venous indwelling catheters for cancer patients. PMID 40377613 · Indian J Cancer · 2025-Jan-01 The study is a randomized trial on catheter maintenance in cancer patients, but it does not meet the core eligibility criteria: it is not a drug intervention trial, does not report a time-to-event efficacy endpoint (like OS, PFS, etc.), and lacks a specified Phase III/IIIb or definitive phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Positron emission tomography versus computed tomography -guided intracavitary brachytherapy for locally advanced cervical cancer: A prospective randomized study. PMID 40214368 · J Cancer Res Ther · 2025-Jan-01 The trial is randomized and reports time-to-event efficacy endpoints (OS, LC) in human oncology patients. However, the randomized intervention is a radiotherapy planning/guidance technique (PET-CT vs. CT), not a drug-containing intervention versus control. Cisplatin is given concurrently to both arms as part of the standard chemoradiotherapy backbone, not as the variable under investigation. Therefore, it does not meet the requirement for a drug-containing intervention as the primary randomized comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial. PMID 39632606 · Cancer · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. PMID 39602111 · JAMA Dermatol · 2025-Jan-01 The study is a randomized, phase 3 trial of a drug (deucravacitinib) in psoriasis, but it is not an oncology study. The primary efficacy endpoints are clinical response rates (PASI 75/90, sPGA 0/1), not time-to-event outcomes like OS, PFS, or DFS. The inclusion criteria require an oncology (malignant neoplasm) study with a time-to-event primary/key secondary efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. PMID 39570620 · JAMA Oncol · 2025-Jan-01 The trial is a Phase 1b study with a primary endpoint of pharmacokinetics and secondary endpoints of safety and response rates. It does not meet the required Phase III/IIIb or Phase II/III criteria, and lacks a time-to-event efficacy endpoint such as OS or PFS.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial. PMID 39535740 · JAMA Surg · 2025-Jan-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Perioperative systemic therapy, current paradigm and ongoing clinical trials in upper tract urothelial cancer. PMID 39444267 · Curr Opin Urol · 2025-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dietary quality and chemotherapy-induced peripheral neuropathy in colon cancer. PMID 39369275 · Cancer · 2025-Jan-01 The record is excluded because the primary endpoint is a safety/toxicity endpoint (time to CIPN), not a primary or key secondary efficacy endpoint (e.g., OS, PFS) required for the Kaplan-Meier digitization cohort. The phase of the trial is also not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiation-emitting metallic stent for unresectable Bismuth type III or IV perihilar cholangiocarcinoma: a multicenter randomized trial. PMID 39311927 · Int J Surg · 2025-Jan-01 The trial meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original results). However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III, IIIb, or II/III). Without this explicit information, it cannot be confirmed as a definitive late-phase trial required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SiLVER randomized clinical trial. PMID 39297745 · Liver Transpl · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Exploring the feasibility of preoperative tumor-bed boost, oncoplastic surgery, and adjuvant radiotherapy schedule in early-stage breast cancer: a phase II clinical trial. PMID 39264581 · Int J Surg · 2025-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Final results of a randomized controlled trial: comparison of the efficacy and safety between totally laparoscopic and laparoscopic-assisted total gastrectomy for advanced Siewert III esophagogastric junction cancer and upper and middle third gastric cancer. PMID 39185962 · Int J Surg · 2025-Jan-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. PMID 39168356 · Int J Radiat Oncol Biol Phys · 2025-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial. PMID 39147209 · Int J Radiat Oncol Biol Phys · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study. PMID 39069239 · Int J Radiat Oncol Biol Phys · 2025-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Interim analysis of short-term outcomes after laparoscopic spleen-preserving distal pancreatectomy with or without preservation of splenic vessels: a randomised controlled trial. PMID 38954668 · Int J Surg · 2025-Jan-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Ultra-short-period perioperative pulmonary rehabilitation on short-term outcomes after surgery in smoking patients with lung cancer: a randomized clinical trial. PMID 38905498 · Int J Surg · 2025-Jan-01 The study is a randomized trial in lung cancer patients, but it is a Phase II or unspecified trial, not Phase III/IIIb. The primary and secondary outcomes are not time-to-event endpoints (e.g., OS, PFS). The intervention is a non-drug perioperative rehabilitation program, not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective Randomized Controlled Trial Comparing Anesthetic Management With Remimazolam Besylate and Flumazenil Versus Propofol During Awake Craniotomy Following an Asleep-awake-asleep Method. PMID 38836295 · J Neurosurg Anesthesiol · 2025-Jan-01 This is an anesthesiology study comparing two sedatives (remimazolam vs. propofol) for awake craniotomy. While it involves oncology patients (brain tumor), the intervention is anesthetic management, not a cancer drug therapy, and the primary endpoint is procedural (time to awakening), not a cancer efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Intravenous Lidocaine, Ketamine, and Lidocaine-Ketamine Combination in Colorectal Cancer Surgery: A Randomized Controlled Trial. PMID 37224065 · Anesth Analg · 2025-Jan-01 The study is a randomized controlled trial in human colorectal cancer patients with a drug intervention. However, it lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The endpoints are inflammatory markers, pain scores, opioid consumption, and gut motility, which are not time-to-event efficacy outcomes. The phase is not specified, so it cannot be confirmed as Phase III/IIIb.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study of comparison of medical thoracoscopic guided biopsy versus closed pleural biopsy for etiological diagnosis of undiagnosed exudative pleural effusions: A randomized controlled study. PMID 39890368 · Indian J Tuberc · 2025-Jan The record describes a randomized, prospective diagnostic study comparing two biopsy techniques for diagnosing the etiology of undiagnosed pleural effusions. While malignancy is a potential cause, the study is not focused on evaluating a cancer treatment. The primary endpoint is diagnostic yield, not a time-to-event efficacy endpoint like OS or PFS. There is no drug intervention; the intervention is a diagnostic procedure (medical thoracoscopy vs. closed pleural biopsy). The study is not a Phase III oncology trial. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. PMID 39878257 · Int J Gynecol Cancer · 2025-Jan 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers. PMID 39867719 · Health Sci Rep · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. PMID 39854659 · JCO Precis Oncol · 2025-Jan The record is a prescreening prevalence study for a Phase III trial, not a report of the trial's time-to-event efficacy results.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cognitive-Behavioral Intervention for Children With Hematological Cancer Receiving Chemotherapy: A Randomized Controlled Trial. PMID 39828642 · Psychooncology · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial. PMID 39820125 · Nat Cancer · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of a developed module in improving quality of life among breast cancer patients undergoing chemotherapy at Institut Kanser Negara. PMID 39812432 · Med J Malaysia · 2025-Jan The study is an original RCT in breast cancer patients with a drug-containing intervention, but its primary efficacy endpoints are quality of life and depression, not a time-to-event outcome (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis. The study phase is not explicitly stated. Therefore, it does not meet the required criteria for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC. PMID 39802818 · JTO Clin Res Rep · 2025-Jan The record describes a secondary analysis of a randomized trial, not the primary or definitive report of the trial's main efficacy results. The trial phase is not explicitly stated in the metadata, making it ineligible under the requirement for Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: A randomized-controlled trial. PMID 39802807 · JHEP Rep · 2025-Jan The study is a randomized controlled trial in oncology (HCC) with time-to-event endpoints, but the intervention is a procedural/ablation technique (MWA vs. RFA) and does not meet the required 'drug-containing intervention' criterion. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial. PMID 39802302 · EClinicalMedicine · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Influence of Regular Statin Intake on Prostate-Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau). PMID 39757796 · Cancer Med · 2025-Jan The record describes a secondary analysis of a drug's effect within a screening trial, not a formal Phase III/IIIb or Phase II/III randomized trial of a novel anti-cancer drug for a definitive oncology indication.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -